SPRING BANK PHARMACEUTICALS, INC. (NASDAQ:SBPH) Files An 8-K Other Events
Item 8.01. Other Events.
On May 23, 2017, the Registrant issued a press release announcing
top-line results from the initial 25mg monotherapy cohort of the
Phase 2a segment of the Registrants ACHIEVE trial, a global,
placebo-controlled, sequential-cohort, double-blind Phase 2
clinical trial, focused on safety and antiviral activity of the
orally-administered selective immunomodulator, SB 9200, in
patients with chronic hepatitis B virus.A copy of the press
release is attached hereto as Exhibit 99.1 and is incorporated
herein by reference.
Item 9.01.Financial Statements and Exhibits.
|
(d) |
Exhibits: |
99.1Press Release issued May 23, 2017.
About SPRING BANK PHARMACEUTICALS, INC. (NASDAQ:SBPH)
Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases. The Company’s SB 9200 selectively activates within infected cells the cellular proteins retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. It also focuses on the use of SB 9200 in other viral diseases, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and latency and hepatitis delta virus (HDV), conducting preclinical research of additional SMNH product candidates or compounds as antiviral therapies and conducting early-stage research programs. SPRING BANK PHARMACEUTICALS, INC. (NASDAQ:SBPH) Recent Trading Information
SPRING BANK PHARMACEUTICALS, INC. (NASDAQ:SBPH) closed its last trading session 00.00 at 12.00 with 9,861 shares trading hands.